特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
253635

下垂体ACTH過剰分泌 (クッシング病) :パイプライン製品の分析

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 42 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
下垂体ACTH過剰分泌 (クッシング病) :パイプライン製品の分析
出版日: 2020年06月30日
発行: Global Markets Direct
ページ情報: 英文 42 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

クッシング病は、下垂体から副腎皮質刺激ホルモン (ACTH) が過剰に放出された状態を指します。にきび、皮膚感染症、腰痛、精神的変化、行動の変化、頭痛などの症状が見られます。治療には、外科手術と放射線療法が含まれます。

当レポートでは、下垂体ACTH過剰分泌 (クッシング病) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤プロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

下垂体ACTH過剰分泌 (クッシング病) の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Alder Biopharmaceuticals Inc.
  • Corcept Therapeutics Incorporated
  • Cortendo AB
  • Cyclacel Pharmaceuticals, Inc.
  • ElexoPharm GmbH
  • Ipsen S.A.
  • Isis Pharmaceuticals, Inc.
  • Novartis AG
  • Orphagen Pharmaceuticals, Inc.
  • Pfizer Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • ALD-1613
  • AT-814
  • ATR-101
  • BIM-23A758
  • COR-005
  • CORT-125134
  • ISIS-GCCRRx
  • ketoconazole
  • mifepristone
  • MPP-482
  • osilodrostat
  • pasireotide LAR
  • Peptides to Antagonize ACTH Receptor for Cushing's Syndrome
  • seliciclib
  • Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease
  • Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease
  • Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism
  • Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Crinetics Pharmaceuticals Inc, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Diurnal Group Plc, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Recordati SpA, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Spruce Biosciences Inc, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, H1 2020
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, H1 2020

List of Figures

List of Figures

  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12320IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion - Pipeline Review, H1 2020, provides an overview of the Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline landscape.

Cushing's disease is a condition which results from hypersecretion of adrenocorticotropic hormone (ACTH) due to pituitary gland tumor. Symptoms include acne or skin infections, backache, mental changes (such as depression, anxiety, or changes in behavior), plethora, menstrual disorders and weight gain. Treatment includes radiation, chemotherapy, and use of certain hormone-inhibiting drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Metabolic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Overview
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development
  • Crinetics Pharmaceuticals Inc
  • Cyclacel Pharmaceuticals Inc
  • Diurnal Group Plc
  • Recordati SpA
  • Spruce Biosciences Inc
  • Strongbridge Biopharma plc
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Drug Profiles
  • Antisense RNAi Oligonucleotide to Inhibit Pro-Opiomelanocortin for ATCH-Dependent Cushing's syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • osilodrostat phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • seliciclib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Silibinin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing Disease and Congenital Adrenal Hyperplasia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tildacerfont - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • veldoreotide ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.